Inovio Pharmaceuticals Inc
INO1.465USD
+0.035+2.43%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
53.72MCap. mercado
PérdidaP/E TTM
Más Datos de Inovio Pharmaceuticals Inc Compañía
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Información de la empresa
Símbolo de cotizaciónINO
Nombre de la empresaInovio Pharmaceuticals Inc
Fecha de salida a bolsaDec 08, 1998
Director ejecutivoDr. Jacqueline Elizabeth Shea, Ph.D.
Número de empleados134
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 08
Dirección660 W. Germantown Pike
CiudadPLYMOUTH MEETING
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal19462
Teléfono18584103134
Sitio Webhttps://www.inovio.com/
Símbolo de cotizaciónINO
Fecha de salida a bolsaDec 08, 1998
Director ejecutivoDr. Jacqueline Elizabeth Shea, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Dr. Roger D. Dansey, M.D.
Dr. Roger D. Dansey, M.D.
Independent Director
Independent Director
8.92K
+32.11%
Ms. Lota S. Zoth, CPA
Ms. Lota S. Zoth, CPA
Independent Director
Independent Director
8.73K
+33.04%
Mr. Jay P. Shepard
Mr. Jay P. Shepard
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Ann Calby Miller, M.D.
Dr. Ann Calby Miller, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. David B. Weiner, Ph.D.
Dr. David B. Weiner, Ph.D.
Director
Director
86.62K
+2.57%
Dr. Jacqueline Elizabeth Shea, Ph.D.
Dr. Jacqueline Elizabeth Shea, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.69K
+28.22%
Dr. Laurent M. Humeau, Ph.D.
Dr. Laurent M. Humeau, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
32.62K
+10.36%
Mr. Peter D. Kies
Mr. Peter D. Kies
Chief Financial Officer
Chief Financial Officer
30.63K
+7.76%
Mr. Simon X. Benito
Mr. Simon X. Benito
Independent Chairman of the Board
Independent Chairman of the Board
12.19K
+21.62%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
10.51K
+25.97%
Desglose de ingresos
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
65.34K
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 27 de jul
Actualizado: dom., 27 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
Accionistas
Accionistas
Proporción
Deep Track Capital LP
6.12%
BlackRock Institutional Trust Company, N.A.
4.22%
The Vanguard Group, Inc.
3.98%
BofA Global Research (US)
2.56%
Geode Capital Management, L.L.C.
1.66%
Other
81.45%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
10.80%
Hedge Fund
6.99%
Investment Advisor/Hedge Fund
5.77%
Research Firm
3.06%
Individual Investor
0.56%
Bank and Trust
0.30%
Venture Capital
0.13%
Pension Fund
0.02%
Other
72.36%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
302
14.08M
27.64%
-1.14M
2025Q1
358
13.94M
38.02%
-1.87M
2024Q4
376
13.66M
38.08%
+2.74M
2024Q3
379
8.99M
34.33%
-1.39M
2024Q2
391
8.36M
32.11%
+1.80M
2024Q1
412
4.61M
19.75%
-2.01M
2023Q4
431
4.68M
20.64%
-2.86M
2023Q3
449
5.16M
23.15%
-3.37M
2023Q2
462
6.56M
29.43%
-5.01M
2023Q1
491
10.80M
49.36%
-1.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Deep Track Capital LP
3.12M
6.12%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.15M
4.22%
+393.45K
+22.37%
Mar 31, 2025
The Vanguard Group, Inc.
2.03M
3.98%
+355.37K
+21.23%
Mar 31, 2025
BofA Global Research (US)
1.30M
2.56%
+664.00K
+103.59%
Mar 31, 2025
Geode Capital Management, L.L.C.
846.80K
1.66%
+218.30K
+34.73%
Mar 31, 2025
Stonepine Capital Management, LLC
518.33K
1.02%
-531.67K
-50.64%
Mar 31, 2025
State Street Global Advisors (US)
514.15K
1.01%
+9.84K
+1.95%
Mar 31, 2025
Northern Trust Investments, Inc.
461.70K
0.91%
+242.90K
+111.02%
Mar 31, 2025
Susquehanna International Group, LLP
194.37K
0.38%
+152.20K
+360.91%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
Avantis US Small Cap Equity ETF
0.01%
iShares Russell 3000 ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
DFA Dimensional US Core Equity Market ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
Avantis US Small Cap Equity ETF
Proporción0.01%
iShares Russell 3000 ETF
Proporción0%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
DFA Dimensional US Core Equity Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Fecha
Tipo
Relación
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
Jan 23, 2024
Merger
12<1
